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Venous thromboembolism (VTE) is a common disease with serious short- and long-term 
complications. VTE is a collective term for deep vein thrombosis (DVT) and pulmonary 
embolism (PE) and is the third most common cardiovascular disease, causing significant 
morbidity and mortality. Despite preventive strategies, the incidence of VTE has been stable 
or increasing slightly during the last decades, affecting 1-2 per 1000 individuals each year. 
Identifying new biomarkers and unraveling underlying mechanisms might help diminish the 
health burden of VTE. The complement system is a cascade system similar to the coagulation 
system.  The two systems have a high degree of crosstalk and are activated together in many 
conditions. Polyphosphates (polyPs) are naturally occurring, highly anionic linear polymers of 
monophosphate units. Short-Chained (SC)-PolyPs are stored and secreted from platelets upon 
stimulation and are reported to inhibit complement activation and to facilitate propagation of 
coagulation activation under experimental conditions. This indicates that SC-polyP might 
modulate the possible link between the two systems, and play a role in the pathogenesis of 
VTE.  
 
The main goals of this thesis were to assess the association between complement activation 
and VTE risk, and to investigate the role of SC-polyPs in the activation of these two systems. 
In paper I, we performed a case-control study to investigate the association between potential 
complement activity and VTE risk. We found that individuals with high potential activity of 
the classical pathway of the complement system and individuals with MBL deficiency had 
higher risk for VTE. In paper II, we conducted a nested-case-control study derived from a 
population-based cohort (The Tromsø Study) to investigate the relationship between 
complement activation and future risk of VTE. We found that high degree of complement 
activation, assessed by plasma terminal complement complex (TCC), was associated with 
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increased risk of VTE, and especially unprovoked VTE.  Results from the whole blood model 
in Paper III showed that SC-polyPs had the ability to activate FXII and did not alter E.coli-
induced complement activation. Our findings suggest that complement activation is involved 
in the pathogenesis of VTE, and that SC-polyP might initiate coagulation activation via FXII 






Venøs blodpropp eller venøs tromboembolisme (VTE) er en sykdom med alvorlige 
komplikasjoner. VTE er en fellesbetegnelse for dyp venetrombose (DVT) og lungeemboli 
(LE) og er verdens tredje vanligste hjerte- og karsykdom. Til tross for økt fokus på 
forebygging har forekomsten vært stabil (om lag 1.5 per 1000 innbyggere årlig) eller økende 
de siste tiårene. Identifiseringen av nye biomarkører kan gi økt forståelse av 
sykdomsmekanismene ved VTE og bidra til bedre risikostratifisering av sykdommen, som 
igjen kan redusere de helsemessige konsekvensene. Komplementsystemet er viktig del av vårt 
immunsystemet. Det er et kaskade system som kan sammenlignes med koagulasjonssystemet, 
og aktiveringer av de to systemene påvirker hverandre i mange situasjoner. Polyfosfater er 
naturlige negativ ladede polymerere bestående av monofosfat. Kort kjedede polyfosfater blir 
utskilt av aktiverte blod plater. Disse er rapportert å hemme komplementsystemet og å 
fremme koagulasjons aktivering. Dette tilsier at polyfosfater kan modifisere samspillet 
mellom komplement- og koagulasjonssystemene.  
 
Hovedmålet med denne avhandlingen var å utforske sammenhengen mellom 
komplementsystemet og risikoen for VTE, i tillegg til å utforske betydningen av kort kjeda 
polyfosfat i aktiveringen av de to systemene. I artikkel I gjorde vi en kasus-kontroll studie for 
å undersøke om den potensielle aktiveringen av de ulike aktiveringsveiene i 
komplementsystemet var assosiert med risikoen for VTE. Vi fant at individer med høy 
potensiell aktivitet i den klassiske veien av komplement systemet og individer med MBL 
defekt hadde en høyere risiko for VTE. I artikkel II gjorde vi en nøsta kasus kontroll studie, 
med deltagere fra Tromsøundersøkelsen, for å utforske om komplement aktivering var 
assosiert med VTE risiko. Vi fant at individer med høy komplement aktivering (TCC) hadde 
en høyere risiko for VTE. Fra fullblods modellen i artikkel III fant vi at kort kjeda 
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polyfosfater aktiverte FXII av koagulasjons systemet, men påvirket ikke E.coli-indusert 
komplement aktivering. Våre resultater tyder på at komplementsystemet kan spille en rolle i 
sykdomsmekanismene ved VTE, og at kort kjeda polyfosfater aktiverer koagulasjonssystemet 
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1. General introduction   
 
Venous thromboembolism (VTE) is a collective term for deep vein thrombosis (DVT) and 
pulmonary embolism (PE). DVT is caused by a thrombus that forms in the deep venous 
system, usually in the lower limbs. A DVT can obstruct the blood flow and cause pain, 
swelling and redness in the affected part. PE primarily occurs when all, or parts, of a DVT 
brake off and travels with the blood stream to the lungs. The clot can lodge in the lungs and 
block the blood flow in the lung [1]. Traditionally PE was thought to be a complication of 
DVT, however, the origin of the PE remains unknown in 50% of patients [2, 3]. DVT is the 
most common of these conditions, accounting for up to two thirds of all VTE events [4].  
 
The pathophysiology of VTE is still not fully elucidated. However, autopsy- and imaging 
studies have shown that venous thrombus formation originates in the valvular sinuses of large 
veins with an intact vascular endothelium in a milieu characterized by severe hypoxia and 
stasis [1, 5, 6]. Studies have shown that the complement is important in ischemic reperfusion 
injury, suggesting that hypoxia may activate the complement system. The complement 
system, which is an important part of the innate and the adaptive immune system, is cross-
linked to the coagulation system in several ways. Few studies have investigated the 
association between complement components and VTE and found that components of the 
complement system are associated with a higher risk of VTE. These studies have raised the 
question of if the complement system is a bystander or a mediator of the VTE risk. It is likely 
that the complement system is involved in early steps in the pathogenesis of the disease. 
Platelets have also been found to play a pivotal role in thrombus formation. Activated 
platelets release short-chained polyphosphates from their dense granules [7]. These inorganic 
polyphosphates have received increased attention in recent years due to their ability to 
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activate the coagulation system. There is a need to further explore the pathophysiology of 
VTE and to discover new players in the formation of the blood clot.     
 
1.1. Epidemiology of Venous thromboembolism  
 
Venous thromboembolism (VTE), occurs in 1-2 per 1000 adults in Western countries each 
year, making it the third most common cardiovascular disease [8]. Although the incidences of 
arterial cardiovascular diseases,  e.g. myocardial infarction and stroke,  have declined by 25-
40% during the last two decades [9], the incidence of VTE remains stable or has even 
increased during the same time period [10, 11].  
 
VTE events can be classified into provoked and unprovoked, depending on the presence of 
predisposing factors during the 3 months before a VTE event [12]. A provoked VTE event 
can occur in the presence of transient or persistent risk factors, and transient risk factors can 
be major or minor [13]. A provoked VTE can occur in the presence of major transient risk 
factors such as surgery with general anesthesia >30min or Cesarean section in the 3 months 
before the event, or in the presence of minor risk factors (i.e. surgery with general anesthesia 
<30min, estrogen therapy, pregnancy) in the 2 months before the event [13]. VTE events can 
also be provoked by persistent risk factors such as paralysis, wheelchair use, active cancer or 
any other ongoing non-malignant condition associated with at least a 2-fold increased risk of 
recurrence after stopping anticoagulant therapy [13, 14]. Population-based studies have 
estimated that about 50-60% of VTE are associated with the presence of provoking factors 
[15-17]. In the absence of a provoking factor, the VTE is said to be unprovoked without any 
obvious cause. The risk of recurrence after a provoked VTE event is generally lower than in 




VTE has major implications for the individual and for society. Short-term complications of 
VTE include thrombus extension, recurrence in the weeks to months after the first event, and 
death. The one-month case-fatality rate after VTE diagnosis is reported to be between 6 and 
11% [15, 19], and the one-year case-fatality rate is between 17 and 23% [15, 19]. A large 
Canadian study reported in 2010, 30-day and one-year case-fatality rates of 10.6% (95% CI 
10.4-10.8) and 23.0% (95% CI 22.8-23.3) respectively [19]. These numbers was confirmed in 
a recent Norwegian study including 710 subjects with incident VTE where the overall 
cumulative mortality rate was 8.5% (95% CI 6.7-11.0) at 30 days and 24.2% (95% CI 21.2-
27.6) at 1 year [20]. In cancer patients, the one-year case-fatality rate is as high as 63-88% 
[15, 21].  
 
Long-term complications of VTE include post-thrombotic syndrome (PTS), chronic 
thromboembolic pulmonary hypertension (CTPH) and late recurrence. The most common 
complication of venous thromboembolism is PTS, affecting 20-50% of patients with DVTs 
and 10-20% of patients with PEs [22]. PTS typically causes chronic pain, swelling and 
changes in the skin in the affected leg [23], but the pathophysiology is not fully understood 
and several mechanisms for PTS have been proposed [24]. The end-point of PTS is venous 
ulcer, which occurs in 5-10% of those with PTS and can be difficult to treat [22, 25]. Risk 
factors for PTS include older age, obesity, proximal DVT location, recurrent DVTs, varicose 
veins, and insufficient anticoagulant therapy, whereas traditional risks factors for VTE such as 
active cancer, surgery, plaster casts or inherited thrombophilias have not been found to 
influence the risk [23, 26]. CTPH is a rare (0.5-4% of PEs), but serious, complication [27, 28]. 
CTPH is caused by a chronic obstruction of major pulmonary arteries when a thrombus fails 
to resolve and undergoes fibrotic transformation [28]. CTPH is characterized by dyspnea, 
discomfort in the chest, and signs similar to right-sided heart failure [29, 30]. Recurrent VTE 
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affects up to one-third of patients during a ten-year period after the first event, with the second 
event tending to occur on the same location as the first (e.g. DVT or PE)[31]. The risk of 
suffering from a recurrent VTE is most likely in the weeks after initial hospitalization after a 
DVT [32].  
 
In addition to the obvious personal consequences for a patient suffering complications after 
experiencing a VTE event, there is also a major economic burden to the society. In a 
Norwegian study using data from two large population based studies, participants with VTE 
had a 62% higher risk of disability pension compared to those not experiencing a VTE [33].    
 
1.2 Pathophysiology of VTE 
 
In 1856, the German scientist Rudolph Virchow proposed a triad for the formation of 
thrombosis. Virchow’s triad proposed that thrombus formation was caused by either changes 
in blood coaguability, changes in the vessel wall, or stasis [6]. Although advances in research 
have provided us with a deeper understanding of thrombosis, this triad still represents a 
cornerstone in our understanding of the pathophysiological mechanisms of VTE.  
 
Figure 1. Virchow’s triad. Three main 
factors contributing to thrombus 
formation: stasis, vessel wall injury, and 
hypercoagulability. (Adapted from Kyrle 





Hypercoagulability or an abnormally increased tendency towards blood clotting plays an 
important part in the pathogenesis of VTE. This can be due to inherited genetic defects such 
as single nucleotide polymorphisms (e.g. Factor V Leiden and prothrombin G20210A) and 
deficiencies in natural anticoagulants (e.g antithrombin, protein C and S)[34]. A 
hypercoagulable state can also be acquired by external factors, and includes obesity, 
pregnancy, oral contraceptives or hormone replacement therapy [35]. Pregnancy, oral 
contraceptives and hormone therapy can lead to a state of hyperestrogenemia, which leads to 
increased hepatic synthesis of procoagulant proteins and decrease the synthesis of 
anticoagulants [35].  
 
An undamaged endothelium expresses various anticoagulants, such as tissue factor pathway 
inhibitor (TFPI), endothelial protein C receptor, thrombomodulin, and heparin-like 
proteoglycans [36]. Damage to the endothelium can lead to tissue factor (TF) expression by a 
variety of vascular cells, which will activate the coagulation cascade [37]. Together factor (F) 
VIIa and TF activate the extrinsic pathway of blood coagulation via activation of FIX and FX. 
A relationship between arterial thrombosis and vessel wall injury is well established, but the 
role of endothelial damage or dysfunction in venous thrombosis is debatable. Sevitt et.al. 
investigated 50 thrombi taken from autopsies, and did not find evidence of endothelial 
damage accompanying thrombi, unless associated with acute insults (i.e. surgery or 
trauma)[5].   
 
The deep recess of the valvular sinuses is recognized as the initiation site of venous thrombus 
formation as confirmed by autopsy and phlebography studies [1, 6].  Prolonged stasis in a 
vein, particular in the deepest recess of the valvular sinuses, causes lowered oxygen tension 
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and cellular hypoxia [1, 38]. This hypoxic state and stasis leads to the upregulation of multiple 
stress-response genes, including hypoxia inducible factor 1-alpha, P-selectin (CD62), and 
other adhesion receptors at the endothelial surface as a response to the oxidative stress [39]. 
The upregulation of stress-response genes leads to a proinflammatory state of the endothelium 
and recruitment and activation of leukocytes (particularly monocytes and neutrophils), 
platelets and the formation of extracellular vesicles (EVs). In addition, it can lead to the 
exposure of TF and initiate the extrinsic pathway of coagulation [38, 40]. Endothelial injury 
may also activate FXII through the exposure of matrix proteins, and contribute to blood 
coagulation through the intrinsic pathway of coagulation [41-43]. FXII can be activated by 
neutrophil extracellular traps (NETs) and in addition, activated platelets can release inorganic 
polyphosphates which can activate the intrinsic pathway [7, 44].  
   
  
 
Figure 2. The pathophysiology of 
venous thrombosis. Blood is trapped 
by a vortex in the valve pocket, and 
gets desaturated and creates a 
hypoxic environment. This activates 
endothelial cells and white blood 
cells, such as monocytes (Mc) and 
platelets (Plt) are recruited. When 
these cells are activated, tissue factor 
bearing extracellular vesicles, also 
called micro particles (MP), bud off 
and contribute to coagulation and 











1.3 Risk factors for VTE  
 
Several acquired and inherited risk factors are associated with VTE. A risk factor is defined as 
any characteristic, attribute, or exposure of an individual that increases the chance of 
developing a disease. For VTE, most often more than one risk factor has to be present for an 
event to occur. This is explained by the thrombosis potential model, which shows how 
combinations of hereditary risk factors, advancing age and provoking factors may yield a 
thrombosis potential exceeding an individual’s thrombosis threshold potential (Figure 3).  
 
 
1.3.1 Heritable risk factors for VTE 
 
Family and twin studies clearly show that hereditary factors are important for the risk of VTE. 
It is estimated that the heritability of VTE is around 50% [45-47]. Non-O blood groups is a 
prevalent genetic trait (present in 60-65%) and individuals with non-O blood group have a 
1.5-2-fold increased risk of VTE compared to individuals with O blood group [48-51]. In a 
Figure 3. The thrombosis potential model. The green line represents intrinsic factors that are 
stable over time such as Factor V Leiden (FVL), and the red line represents the effect of a risk 
factor that increases over time, like age. The orange line demonstrates the joint effects of FVL 
and age in combination with provoking factors. Provoking factors early in life may not be 
enough to reach the thrombosis threshold. However, a provoking factor later in life may exceed 
the thrombosis threshold and results in a VTE. If the thrombosis potential remains increased 
following a VTE event, a provoking factor may exceed the thrombosis threshold again and 
result in a recurrent VTE (adapted from Rosendaal, Lancet 1999). 
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large meta-analysis, non-O blood group (A1 and B) was present in 70% of VTE cases and 
54% of controls [50]. The increased risk of VTE associated with non-O blood group is partly 
mediated through increased levels of von Willebrand factor (vWF) and FVIII [49, 52]. 
However, when vWF and FVIII were taken in to account in the risk analysis, non-O blood 
group were still associated with increased risk of VTE, suggesting that other mechanisms are 
also involved [53, 54].  
 
Factor V Leiden (FVL) is a mutation in the FV gene, which leads to reduced ability of FV to 
be inactivated by activated protein C (APC) [55, 56], and is associated with a 3-fold increased 
risk of having a VTE [47]. The mutation is present in approximately 5% of the Caucasian 
population in heterozygous form [48, 56, 57]. Homozygous form of FVL is far less common 
[57], but individuals with homozygous FVL have a higher risk of VTE compared to 
heterozygous individuals [58]. Those with homozygous form of FVL experience thrombosis 
at a younger age and they have a higher rate of recurrence of VTE than controls [59]. The 
“FV Leiden paradox” refers to the fact that FVL is associated with a higher risk of DVT than 
PE [60]. FVL has a synergistic effect with other factors such as oral contraceptives [61, 62], 
pregnancy [63], smoking [64], obesity [64] and cancer [65] on the risk of VTE.  
 
Increased levels of coagulation factors are associated with a higher risk of VTE [66].  
Prothrombin 20210A is a mutation is present in approximately 2% of the Caucasian 
population [48, 67], leads to increased levels of plasma prothrombin levels [68] and is 
associated with a 3-fold increased risk of VTE [68]. The mutation is due to a single base pair 
substitution at nucleotide position 20210 located at the 3’ untranslated region of the non-




Protein S and C serves as regulators of the coagulation cascade, and deficiencies in these are 
present in less than 1% of the general population [69]. Activated protein C (APC) and its 
cofactor protein S inactivate FVIII and FV [48]. Several gene mutations can lead to protein C 
and S deficiencies, and heterozygous carriers have up to a 10-fold increased risk of VTE [69]. 
Gene mutations that lead to antithrombin deficiencies are associated with a 10- to 30-fold 
increased VTE risk [70]. Such mutations are very rare and are present in 0.02 to 0.2% of the 
general population [70-72].  
 
In the 2000s genome-wide association studies became available and since then additional 
gene variants associated with VTE have been discovered. By 2015, 17 genes with genetic 
variations associated with VTE risk had been identified [47]. In the future, novel genetic 
factors are expected to be identified. These factors may potentially include weak genetic 
factors as well as genetic factors associated with a high risk of VTE.   
 
1.3.2 Acquired risk factors for VTE 
 
Several acquired risk factors exist for the development of VTE. Age, obesity, height, cancer, 
immobilization, surgery, trauma, pregnancy, puerperium, and use of oral contraceptives are 
among the acquired risk factors of VTE. Some of these are classified as being provoking 
factors, either transient (e.g. pregnancy, surgery) or persistent (e.g. active cancer, 
inflammatory bowel disease), while male sex and older age are risk factors that are not 
considered as provoking factors [13].  
 
A major acquired risk factor for VTE is age, and the risk of VTE increases exponentially with 
increasing age. The annual incidence of VTE in young adults (20-30 years) is 1 in 10000, in 
middle aged (50 years) is 1 in 1000 and in elderly (>75 years) is 1 in 100 [1, 73]. It is not 
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clear why the risk of VTE increase exponentially with age, but a possible explanation is age-
related increase in procoagulant proteins such as fibrinogen, FVIII and FIX [74]. Older people 
also have increased levels of interleukin (IL)-6 and C-reactive protein (CRP) which indicates 
an increased inflammatory state [74]. Age related changes in the vessel wall and valves may 
also be involved [1]. The elderly are also less physically active [75], which leads to more 
immobility, and as a consequence the muscle strength can get weaker which can contribute to 
the increased VTE risk.  
 
Obesity, defined as a body mass index (BMI) of >30kg/m2 is associated with a 2-3 fold 
increased risk of VTE [76]. Mendelian randomization studies have found that there is a causal 
relationship between high BMI and VTE risk [77] and that 30% of the VTE risk can be 
explained by obesity. Other measurements of obesity have also been investigated, and in the 
Tromsø study, waist circumference yielded the highest risk estimate for VTE, and identified 
most subjects at risk [78]. Not only obesity, but also weight gain is a risk factor for VTE [79]. 
In many populations, BMI is high, and obesity continues to increase, this constitutes a major 
challenge [80, 81]. Possible mechanisms behind the association between obesity and 
increased VTE include venous stasis due to increased intraabdominal pressure and 
inflammatory properties of adipose tissue [82].  
 
Height is another anthropometric measure associated with VTE risk [83, 84]. In the Tromsø 
Study, the risk of VTE increased by 34% per 10cm increase in height in men [83], and recent 
Mendelian randomization studies have confirmed this estimate [85]. Possible mechanisms for 
this association might be that taller people have more valves and greater venous surface 
compared to shorter people, and that there is greater hydrostatic pressure and venous stasis in 




Cancer is recognized as a major risk factor for VTE, associated with a 5-7 fold increased risk, 
and overall, cancer is associated with 20-25% of all incident VTEs [15, 16, 87, 88]. The risk 
of cancer-associated VTE is highest the first months after cancer diagnosis but remains 
elevated for years [89]. The VTE risk differs among histological subtype, cancer stage, and 
time since cancer diagnosis. Hematological malignancies and cancers of the lung, 
gastrointestinal tract, and brain are high risk sites [4, 89], and metastatic cancers yield a 
higher VTE risk that localized cancers [89]. The high risk of VTE in cancer patients might be 
due to tumor-derived procoagulant factors, such as EVs positive for TF, inflammation, and 
activation of neutrophils [90]. In addition, cancer patients are often hospitalized, undergo 
surgery, and are prone to infections and to be immobilized.  Treatment related risk factors 
include chemotherapy, radiotherapy, and central venous catheters. 
 
Immobilization is a consequence of many medical conditions and has been associated with a 
2-fold increased risk of VTE [91] and a 6-fold increased risk of DVT [92]. A recent study 
using the Tromsø Study found a 73-fold increased risk of VTE in immobilized patients [93] . 
Venous stasis is thought to be the reason for the increased risk of VTE when immobilized. 
Hospitalization is also a major risk factor for VTE, and hospitalized patients have >100 fold 
higher risk of VTE compared to residences in the community [94].  
 
Major surgery is a strong risk factor for VTE and is associated with a 4-22 fold increased 
VTE risk [95, 96]. Surgical procedures associated with a high VTE risk include neurosurgery, 
major orthopedic surgery of the leg, cancer surgery of the thorax, abdomen or pelvis, and 




When screening systematically for VTE in trauma patients not receiving thrombosis 
prophylaxis, VTE was found in more than 50% [98].  One study found that even with 
thromboprophylaxis 1/3 of patients developed DVT after major trauma [98, 99].  
 
Serious medical conditions including rheumatic disorders, ischemic stroke, myocardial 
infarction, congestive heart failure, and respiratory disease [100] are recognized as risk factors 
for VTE. Infection is also identified as an independent risk factor for VTE. A recent study 
showed that acute infection in hospitalized patients was a strong trigger for VTE (20-fold 
increase), and that immobilization and acute infection had a more than additive effect on VTE 
risk (141-fold increased VTE risk) [93].   
 
1.4 The coagulation system   
In 1964, two groups simultaneously proposed a cascade or waterfall model of blood 
coagulation. The models consisted of a series of steps in which activation of one coagulation 
factor lead to the activation of another, finally resulting in thrombin generation and fibrin clot 
formation [101, 102]. They proposed that each coagulation factor existed as a proenzyme that 
could be converted to an active enzyme upon activation. This concept has later been modified, 
and clotting factors that were thought to be enzymes have later been found to work as 
cofactors and do not possess enzymatic activity (FVIIIa was found to be a cofactor for FIXa 
and FVa for FXa) [103]. Two pathways of coagulation have been described: the 
extrinsic/tissue factor pathway and the intrinsic/contact activation pathway. These two 
pathways converge, forming the common pathway, which results in the activation of FX to 
FXa [104]. FXa converts prothrombin to thrombin [105] and finally thrombin converts 
fibrinogen to fibrin which is the main component of the venous clot [1]. Thrombin cleaves 
plasma soluble fibrinogen into Aα and Bβ polypeptides which in turn release fibrinopeptide A 
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and B. The release of fibrinopeptides results in the formation of fibrin monomers.  The fibrin 
monomers then polymerizes to form a gel of fibrin polymers that traps blood cells [106] . In 
addition, thrombin activates FXIII to FXIIIa, which in turn mediates the covalent cross-
linking of the fibrin polymers to form a stable fibrin clot [107].  
 
The extrinsic pathway, also called the tissue factor pathway, is activated at the site of injury 
due to the exposure TF on extravascular cells. TF (also known as FIII, CD142, or 
thromboplastin) is a transmembrane protein which acts as a receptor and a cofactor for 
FVII/FVIIa and is recognized as the main contributor for initiating hemostasis, [108] the 
process that protects the body for injury due to bleeding. Upon injury to the endothelium 
followed by expression of TF, plasma containing FVII/FVIIa comes into contact with TF 
Figure 4. Outline of the coagulation 
cascade in hemostasis. The first traces of 
FXa form a complex with TF-FVIIa-
TFPI, which turns off the function of TF. 
FVa generated from platelets upon 




[109]. FVIIa at natural biological concentrations is not sufficient for activating FIX or FX, TF 
binding is necessary for activation of FIX and FX [110]. Once bound to TF, FVII is rapidly 
converted to FVIIa [111] and the TF-FVII/FVIIa complex activates FIX and FX [37] leading 
to the common pathway of coagulation. The majority of FVII circulates as a zymogen, but 
there are also small amounts of plasma FVIIa in healthy individuals [112], thus there are two 
possible ways to form the TF-FVIIa complex, either by direct capture of circulation FVIIa, or 
by capture of FVII by TF followed by conversion of bound FVII to FVIIa. Once sufficient 
amounts of FXa are formed and the TFPI-FVIIa-TF-Xa complex is formed, the TF pathway is 
turned off and FXa is responsible for maintaining hemostasis (Figure 4).    
 
The cell-based model of blood coagulation [113] emphasizes the interaction between 
coagulation factors and specific cell surfaces (e.g. platelets and monocytes). This model was 
developed, in part, for cell-based experimental models that used monocytes [114-116], or 
fibroblasts [113] as a source of TF and activated platelets as a surface for thrombin generation 
[117]. In this model, coagulation occurs in three overlapping steps; initiation, amplification, 
and propagation, and requires two types of cells: TF-bearing cells and platelets. [117]. Small 
amounts of thrombin generated on TF-bearing cells in the initiating phase of coagulation 
amplify the initial procoagulant signal by enhancing platelet adhesion [118], and activation 
[116]. When platelets are activated they release FVa from α-granules onto their surface and 
the enzyme complex of FXa and prothrombin assemble to form the initial prothrombinase 
[119]. Thrombin cleaves vWF bound FVIII thereby releasing it from vWF and activating it 
[113]. By the end of the amplification phase, activated platelets with bound FXIa [120] , FVa 
[121] and FVIIIa [113] set the stage for thrombin activation in the propagation phase, which 
occurs on the surface on activated platelets expressing phosphatidylserine (PS). During the 
propagation phase, FIXa binds to FVIIIa on the platelet surface, and the FIXa/FVIIIa complex 
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activates FX to FXa. The binding of FX by FIXa/FVIIIa complex is dependent on PS. FXa 
can then bind to its cofactor FVa, and the FXa/FVa complex bound to PS on the platelet 
surface, can produce thrombin in sufficient amounts to clot fibrinogen and feedback activate 
FXI [113]. A similar mechanism is probably involved in the hemostatic mechanism when 
there is a vessel wall injury whereby TF, located in adventitia is exposed to blood, and 
platelets are activated by interaction with collagen at the site of injury.  
 
The cellular origin of TF in circulating blood is a matter of debate [122]. Studies have 
reported TF expression in platelets [122], neutrophils [122] and eosinophils [123]. Other 
studies have failed to detect TF expression in platelets [122, 124, 125], neutrophils [122, 125, 
126] and eosinophils[127]. The discrepancies of TF in these cells may be due to non-specific 
assays [128] or non-specific binding of the TF-antibody used [129]. However, activated 
monocytes are shown to be the main source of TF in blood [130], and constitutively express 
small amounts of TF under basal conditions [122, 125, 126]. EVs can display TF on their 
surface and can be a source of TF in plasma [131].  
 
In 1967, Peter Wolf identified what he called “platelet dust” while studying coagulation [132]. 
This was later identified as extracellular vesicles (EVs) which is a general term enveloping 
exosomes and microvesicles released from blood cells and tissues upon activation or 
apoptosis [133]. Studies have shown that elevated plasma levels of EVs are associated with 
several diseases, including: antiphospholipid syndrome [134], heparin-induced 
thrombocytopenia [135], hypertension [136], myocardial infarction [137] acute ischemic 
stroke [138], sepsis [139] and HIV infection [140].  EVs are highly procoagulant due to 
negatively charged phospholipids, PS and polyphosphates (polyPs) together with TF on their 
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surface [131]. Growing evidence from observational- [141, 142], and experimental studies 
[143-145] suggest that EVs are involved in the pathogenesis of VTE.  
 
The intrinsic pathway is activated when FXII comes into contact with negatively charged 
surfaces such as long-chained inorganic polyPs, materials in medical devices [146, 147], 
microbial cell wall and surfaces [148], damaged tissues [149], and activated platelets [7]. This 
pathway commences with the contact phase, in which factors prekallikrein (PK), high molecular 
weight kininogen (HK), FXII, and FXI are exposed to a negatively charged surface. FXII then 
undergoes a conformational change with HK as a cofactor, which generates small amounts of 
activated FXII (FXIIa). Once small amounts of FXIIa accumulate, it cleaves plasma PK to 
plasma kallikrein, which again activates FXII and generates a positive feedback loop of FXII 
activation. FXIIa together with HK cleaves FXI, to generate activated FXI (FXIa). FXIa 
initiates a series of Ca2+-dependent sequential proteolytic cleavage events that lead to thrombin 
generation, fibrin formation, and production of a fibrin clot in plasma [150]. Thrombin is 
responsible for the conversion of fibrinogen to fibrin [37, 151], which makes up the majority 
of a venous blood clot. 
 
The intrinsic pathway may be the most important player in thrombus formation. Recent 
animal studies of experimental thrombogenesis suggest that this pathway of blood coagulation 
may play a pathogenic role in human thrombosis [152]. Cheng et al. found that FXII-deficient 
mice were more resistant to the development of thrombosis than both FXI- and FIX-deficient 
mice [153]. This suggests that FXII may exert additional effects on thrombosis, independent 
from activation of FXI. The role of FXII in thrombosis has been supported by several 
additional studies. Cai et al. demonstrated that total protection against thrombosis (by 
arteriovenous shunt and the FeCl3-mediated arterial thrombosis models) could be attained in 
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FXII knockout rats [154].  Xu et al. showed that the administration of infestin-4 (a 
competitive FXIIa inhibitor) produced a considerable and dose-dependent reduction of clot 
weight in an arteriovenous shunt thrombosis model in rats and rabbits [155]. Finally, Larsson 
et al. developed a FXII function-neutralizing antibody and showed that inhibition of FXIIa-
mediated blood coagulation was effective to abolish thrombus formation under flow in both 
rabbits and mice [146]. Factors FXII and FXI have been proposed as new targets for 
anticoagulant therapy, with FXI being the most promising of the two. By blocking FXII or 
FXI the risk of VTE is reduced and at the same time major bleeding is avoided [156].  
 
Coagulation is resolved by fibrinolysis, which involves an enzymatic cascade that leads to the 
removal of fibrin deposits  [157]. The key component of fibrinolysis is plasminogen, zymogen 
of the serine proteinase plasmin. Plasminogen is converted to plasmin by tissue plasminogen 
activator (tPA) and urokinase plasminogen activator (uPA) [157, 158]. Through positive 
feedback, plasmin cleaves both tPA and uPA, making them more active two-chained 
polypeptides [159]. Once formed, plasmin cleaves fibrin to soluble degradation products, 
exposing carboxy-terminal lysine at which tPA and plasminogen can bind. This leads to 
enhanced plasmin generation and fibrin removal. The binding of tPA and plasminogen to fibrin 
can be blocked by thrombin-activatable fibrinolysis inhibitor (TAFI) [159]. As the name 
implies, TAFI is activated by thrombin, and activation leads to the removal of carboxy-terminal 
lysine and the attenuation of plasmin generation and stabilizing the fibrin clot [159]. 
Plasminogen inhibitors such as plasminogen activator inhibitor-1 (PAI-1), and inhibitors of 
plasmin (α2-plasmin inhibitor) also regulate fibrin dissolution [159]. Hemostasis involves a 




The coagulation system is regulated at several steps in the cascade. Tissue factor pathway 
inhibitor (TFPI) inhibits the extrinsic pathway by binding directly to, and inhibiting the TF–
FVII/FVIIa complex [160]. The effect of TFPI is dependent on the formation of the FXa-TFPI-
FVIIa-TF complex, thus FXa is necessary for TFPI function. TFPI also inhibits and interacts 
with FXa alone.  A threshold effect between low levels of TFPI and increased risk of VTE has 
been proposed [161, 162], and heterozygote TFPI deficiency has been shown to be more 
common in thrombotic patients compared to controls [163]. Antithrombin inhibits thrombin 
and FXa, and is one of the most important natural proteins responsible for the prevention of 
spontaneous intravascular clot formation [164]. Deficiency of antithrombin results in an 
increased risk of venous thromboembolism. The protein C anticoagulation pathway is one of 
the most important antithrombotic pathways. Activated protein C (APC) functions as an 
anticoagulant by inactivation of FVa and FVIIIa in the presence of protein S [165]. 
 
1.5 The complement system  
 
In the late 1800s the bacteriologists, Paul Ehrlich, Jules Bordet, and George Nuttal identified a 
heat liable substance in serum, which killed bacteria. They called it “alexine” which means 
“defender of man”. Several years later Ehrlich replaced “alexine” with “complement” [166]. 
It took more than 50 years after the first discovery until Pillmer discovered the next part of the 
complement system in 1954. He found properdin, when isolating C3 from serum, which later 
was proven to be an important part of the alternative pathway [167] . Kawasaki et al. found 
the MBL protein in 1978, but its function and the lectin pathway, was discovered as late as in 
1989, by Super et al., and later elaborated by Matsushita et al. [166, 168]. 
 
The complement system consists of more than 50 components, including complement 
recognition molecules, proteases, enzyme complexes and biologically active split products as 
29 
 
well as soluble and membrane bound receptors and regulators. The major source of 
complement proteins found in plasma is the liver, with the exception of C1q, properdin and 
C7, which are predominantly synthetized in bone marrow derived cells, and factor D, which is 
synthetized in adipocytes [169-171]. The complement system is an important component of 
the innate immunity and is a link between the innate- and adaptive immune system. It is a 
cascade system comparable to the coagulation, fibrinolytic, and the kallikrein-kinin systems, 
with its components found both in circulation and in tissues. It is highly effective in the 
destruction of invading microorganisms, the elimination of immune complexes, and the 
clearance of damaged host cells [172].  
 
 
Figure 5. An overview of the complement system. The classical, lectin, and alternative pathways converge into a 
final common pathway when C3 convertase cleaves C3 into C3a and C3b. Details are explained in the text. Ab = 
antibody, CRP= C-reactive protein, SAP = serum amyloid protein, C1-INH = C1 inhibitor, MBL = mannose-
binding lectin, MASP = MBL-associated serine protease, TCC= Terminal Complement Complex. (Kindly 
provided by Prof. T.E Mollnes).  
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The complement system is activated by three pathways: the classical pathway, the lectin 
pathway, and the alternative pathway (Figure 5). 
 
The classical pathway is activated by binding of C1q to antibodies on a pathogenic surface 
and by antibody-independent mechanisms. C1q binds efficiently to single IgM molecules, but 
requires hexamers of IgG molecules for similar efficient binding [173]. Antibody-independent 
activation of the classical pathway can occur via bacterial products, pentraxines (including 
CRP), and apoptotic and necrotic cell components like annexins, DNA, and histones [174]. 
C1q circulates in a surveillance mode in complex with C1r and C1s. When C1q binds to its 
target, it undergoes a conformational change and auto activates the serine proteases C1r and 
C1s [175]. C1s cleaves C4 into C4a and C4b, and leads to further association and cleavage of 
C2, leading to assembly of the C3-convertase: C4b2a, which cleaves C3 to C3a and C3b 
which leads to the formation of the C5 convertase C4b2a3b [176].  
 
The lectin pathway is activated by the recognition of pathogens via pattern-recognition 
molecules (PRM) of the lectin type via pattern-recognition receptors (PRRs) [177]. The first 
PRM discovered was mannose-binding lectin (MBL) and later several other PRMs including 
ficolin 1-, 2-, 3 and several collectins were found [178]. The lectin pathway can also be 
involved in the clearance of apoptotic cells [179], and bind self-structures as mitochondria 
[180] and DNA [181].  MBL is analogous to C1q and triggers three MBL-associated 
proteases (MASPs). MASP-1 and -2 cleave C4 and C2 in a calcium-dependent manner and 
the subsequent steps of the lectin pathway are identical to the classical pathway with assembly 




The alternative pathway is activated by spontaneous hydrolysis of the internal thioester bond 
in C3[177], which creates C3(H2O), a C3b-like molecule. Factor B is recruited and binds 
factor D in a magnesium-dependent manner. Factor B is cleaved by factor D to Bb and Ba, 
resulting in the formation of the alternative pathway C3-convertase C3(H2O)Bb. The 
alternative pathway can also use C3b produced by either pathway to bind factor B, and 
forming the C3 convertase C3bBb. Properdin, the only positive regulator of complement, 
binds to C3bBb and stabilizes this complex which cleaves C3 and binds to C3b to form the 
C5 convertase C3b2BbP, which cleaves C5 in the same manner as the classical- and lectin 
pathway C5 convertase [176].  The spontaneous hydrolysis of C3 can be termed a “tick-over” 
and ensures that the complement system is always ready to react [182]. The alternative 
pathway is an amplification loop of complement activation. Positive feedback from C3bBbP 
results in further cleavage C3 and production of additional C3bBb, consequently, this 
pathway is responsible for the vast majority of C3b and C5b-9 formation, independent of the 
initiating pathway [183]. 
 
Irrespectively of which pathway of complement that is activated, the three activation 
pathways converge at the formation of C3 convertase, the formation of opsonins (C3b), 
anaphylatoxins (C3a and C5a) and the terminal C5b-9 complex (TCC). [177].  
 
The anaphylatoxins C3a and C5a are small peptides with important signaling properties. They 
bind to their respective receptors, C3aR, C5aR1 and C5aR2 on immune cells, and several 
other cell types [184]. The effect of binding of these anaphylatoxins depends on the cell type 
expressing the receptors. C3a was previously thought of as a strictly proinflammatory 
molecule, but was recently shown to also exert anti-inflammatory properties especially in 
neutrophils while still showing proinflammatory effects on monocytes, eosinophils and mast 
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cells [185]. C5a is regarded as the dominant proinflammatory effector-signaling molecule of 
the complement system. It acts as a chemotactic agent on neutrophils and monocytes and 
induces oxidative burst, induces upregulation of adhesion molecules and the release of 
enzyme-containing granules and cytokines [186]. C5a has also anti-inflammatory and immune 
regulatory effects when binding to C5aR2 [187].  
 
The end stage of complement activation is the formation of the terminal TCC complex C5b-9. 
The TCC assembles when C5b associates with C6, C7, C8, and multiple C9 molecules. If 
assembled on a surface, the binding of C7 leads the addition of several C9 molecules which 
forms a pore through the membrane. This is the Terminal complement complex (TCC), also 
called the membrane attack complex (MAC). This pore can lyse cells and bacterial 
membranes [188]. If the terminal pathway is activated in the fluid phase, the TCC complex 
will build up in a soluble form, sC5b-9, that can be measured in plasma as an indicator 
complement activation, although no biological function is known for sC5b-9. Notably, lysis is 
not the only effector function of the TCC. Sublytic C5b-9 inserted into a cell membrane can 
induce proinflammatory responses including NLRP3-inflammasome activation and 
degranulation [189, 190].  
 
To protect the host tissue and cells from damage, the complement system is tightly regulated. 
Several surface-expressed complement inhibitors that limit the activation of this system to the 
site of infection are found on host cells. Thus, complement regulators mainly acting as 





C1-INH is a serine protease inhibitor, which inactivates C1r and C1s of the classical pathway 
and the MASPs in the lectin pathway. C1-INH also inactivates serine proteases of other 
cascades, such as the contact pathway of the coagulation system and the fibrinolytic system, 
and is therefore not strictly a complement inhibitor [191].  
 
The regulation of the formation of C3 convertase, and thus the cleavage of C3 is essential 
[192] in complement activation, and factor H is a key player in the regulation of this step 
[192, 193]. Factor H binds and protects self-surfaces from complement deposition by binding 
to C3b, accelerating the decay of the alternative pathway C3 convertase (C3bBb) and acts as a 
cofactor for factor I mediated proteolytic degradation of C3b [194]. Factor I (FI) is a fluid 
phase serine protease which cleaves and inactivates C4b and C3b [195] and the inactivated 
products (C4c, C4dg, iC3b, C3c and C3dg) can no longer assemble to the C3-convertases to 
further drive the cascade. C4BP is a major soluble inhibitor of both the classical and the lectin 
pathways of complement [196]. It exerts its inhibitory action by binding to and limiting the 
function of activated complement component C4b. C4BP acts as a cofactor for FI in the 
inactivation of soluble and cell-bound C4b [197]. Membrane cofactor protein MCP (CD46) 
also acts as a cofactor for FI-mediated cleavage of C4b and C3b. As its name implies, this is a 
membrane bound regulator, expressed on all cell types except erythrocytes [198]. 
 
Decay accelerating factor (DAF; CD55), is a membrane bound regulator, which binds to and 
dissociates the alternative pathway C3-convertase. CD59 prevents final assembly C5b-9 on 
cell membranes, thus preventing lysis [198](37). 
 
In addition to the immune and inflammatory roles, the complement system has been found to 
play a role in metabolism, hematopoiesis, reproduction, central nervous system development, 
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liver regeneration, apoptosis, and of particular interest here, coagulation [199].  Conditions 
which leads to a hyperactive complement system, are increasingly recognized as contributors 
to vascular and thromboembolic diseases, such as paroxysmal nocturnal hemoglobinuria, 
atypical hemolytic uremic syndrome [200] , and antiphospholipid syndrome [201].  
 
1.5.1 Crosstalk between the complement and coagulation system  
 
The convergence between complement and coagulation extends far beyond the chemical 
nature of the complement and coagulation components (Figure 6), both of which form 
proteolytic cascades [202]. The endothelium and circulating cells all have the machinery to 
initiate, activate and respond to effectors generated from activation of both systems [203]. 
The two systems system appear to be triggered simultaneously by several conditions, e.g. 
severe tissue injury [202, 204], acute trauma [205], or during systemic inflammation [206], 
which is beneficial for the host. On the other hand, dysregulation of one system, might result 
in escalating activation of both, which might end in tissue damage from inflammation or 
thrombosis [207]. The term thromboinflammation is important to mention when discussing 
the crosstalk between the complement and coagulation systems. Thromboinflammation is part 
of the repair process after damage, and describes the crosstalk between complement, 
coagulation, and platelets on one side, and leukocytes and the endothelium on the other [208]. 
Thromboinflammation is associated with thrombotic events such as cardiac infarction, stroke, 
and other cardiovascular conditions [209].  
 
The endpoint of complement activation, with release of C5a and TCC formation can enhance 
blood clotting by several mechanisms. Incorporation of TCC as MAC into the platelet 
membrane activates platelets and results in 1) the exposure of negatively charged lipids [210] 
and TF [202] on the platelet surface, 2) the release of TF-positive MVs [211], and 3) dense 
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granule secretion from the platelet cytoplasm [212].  TCC also induces permeability changes 
in the vessel wall [202, 213]. C5a modifies the activity of mast cells and basophils to expose 
plasminogen activator inhibitor-1 (PAI-1) which inhibits fibrinolysis [214, 215]. C5a induces 
a “switch” in mast cells from a profibrinolytic (t-PA release) to a prothrombotic phenotype 
(PAI-1 release) and induces neutrophils and monocytes to expose TF [202] (Figure 6),  thus 
modifying the balance between coagulation and fibrinolysis.  
 
 
Figure 6. Overview of complement–coagulation and platelet crosstalk (Markiewski, Trends in immunology 
2007).  
 
Factors of the coagulation system have complement activating properties. Kalowski et al. 
reported in 1975 that thrombin and thromboplastin injected into rabbits led to activation of the 
complement system through C3 [216]; they concluded that complement activation occurs 
concomitantly with intravascular clotting when induced in vivo. This was confirmed by 
evidence of thrombin-mediated cleavage of C3 into in a dose- and time-dependent manner in 
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human serum [217]. In addition, kallikrein and plasmin, has been shown to directly activate 
C3 and C5 [218, 219]. Several studies have shown that enzymes other than complement can 
activate C5 independently of C3 [220-222], among these, thrombin has been proposed as a 
potential potent C5 convertase, in the absence of C3 [222]. Finally, factor XIIa of the intrinsic 
coagulation pathway is able to activate the classical complement cascade through the 
activation of C1q [219].  
 
The complement systems possible effect on platelet activation has been extensively studied 
[203]. Binding of iC3b, C3d and C3dg to complement receptor (CR)-2 activates platelets 
[223] and several studies have showed the presence of the C1q receptor gC1qR/p33 and 
cC1qR on platelets, and found that binding of C1q mediates platelet aggregation and 
activation [224-226]. In vitro studies have found the presence of receptors for C3a and C5a on 
the platelet surface [227, 228]. The discovery of several complement inhibitors on human 
platelets, including Factor H [229, 230], points towards the complement system’s importance 
for platelet function. Platelets can also activate the complement system through P-selectin, 
and activated platelets generate C3a [231]. In addition, thrombin receptor-activating peptide 
(TRAP)-6 activated platelets activate the complement system by releasing chondroitin sulfate 
[232].  
 
The effect of complement on platelets is interesting in the case of VTE, since both elevated 
platelet count [233, 234] and mean platelet volume [234, 235] are associated with increased 
risk of VTE.  The classical function of platelets is to cover and close endothelial and tissue 
wounds [236, 237]. In addition to wound closure, which is followed by stable thrombus 
formation, platelets contribute to long-term healing and regenerative mechanisms [238, 239]. 
However, if platelet activation occurs without proper regulation or at improper locations, 
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thrombus formation by activated platelets can result in life-threatening events such as 
myocardial infarction, stroke, or atherosclerotic plaques rupture [240-242].   
 
 
1.5.2 The complement system and risk of VTE 
 
Although many risk factors for VTE have been identified, there are still a considerable 
number of events that are considered to be unprovoked without known predisposing factors 
[32]. The cellular and molecular mechanisms behind the initiation of thrombus formation are 
still not fully understood. In light of the close interactions between coagulation and 
complement, it is reasonable to think that the complement system plays a role in the 
pathogenesis of VTE.   
 
Autopsy- and imaging studies suggest that formation of venous thrombi originate in the valvular 
sinuses of large veins. The milieu in the valvular sinuses is characterized by severe hypoxia and 
stasis, conditions known to induce cellular immune responses [1, 5, 6]. As the complement 
system is an important player in the immune system and is also activated by hypoxic cells and 
tissues, one can assume that the complement system is activated in the hypoxic milieu in the 
valvular sinuses. Activated complement can promote activation of the coagulation system, 
which can lead to thrombus formation if not counterbalanced by regulatory mechanisms. 
Results from observational and animal studies suggest that the complement system is involved 
in the early steps in the pathogenesis of VTE. In a large population-based cohort study, subjects 
with plasma complement C3 concentration in the highest tertile had 31% higher risk of VTE 
compared to those in lowest tertile [243]. This study led to the question if C3 was a bystander 
or a mediator of the VTE risk. The role of C3 as a mediator of VTE risk was demonstrated in a 
TF-dependent mouse model of flow restriction-induced venous thrombosis [244]. C3-deficient 
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mice had lower incidence of venous thrombosis and reduced thrombus size, compared to wild-
type mice. In addition, C5-deficient mice had a significantly reduced clot burden after 48 hours 
compared to wild type [244]. Further, in a cross-sectional study of patients with systemic lupus 
erythematosus (SLE), patients with a previous history of VTE showed increased deposition of 
complement factors C1q, C4, and C3 on platelets [245].   
 
In light of these studies one can draw the conclusions that C3 and C5 are involved in thrombus 
formation, but the mechanisms are not understood. C3 and C5 are central molecules and do not 
show which pathway is activated, or if the complement system activation is sufficient to 
generate the TCC. These questions, if answered can future explore the link between the 
complement system and its role in VTE. To date there are no studies that have investigated 
complement pathway activity or, the overall complement activation and risk of VTE.  
 
1.6 Polyphosphates  
 
Inorganic polyphosphates (polyPs) are linear polymers of orthophosphate, linked by 
phosphoanhydride bonds. They are found in all mammalian cells and lower organisms and they 
are shown to have proinflammatory and prothrombotic effects [246].  The polymer varies in 
length from cell to cell and in different organisms, ranging from 60 to 100 units in human 
platelets and up to thousands of phosphate units in bacteria [246]. Platelets release polyPs from 
their dense granules upon activation, which, play a role in a variety of hemostatic and 
thrombotic mechanisms. In addition, as discussed above, activated platelets are associated with 
increased risk of VTE. As a result, polyphosphate has been proposed as a potential druggable 






Figure 7. The roles of polyP in blood clotting vary depending on polymer length. (A) Bacterial long-chain polyP 
acts at 4 points in the clotting cascade, indicated in red: 1 initiates the contact pathway of blood clotting via FXII; 
2, accelerates factor V activation and abrogates TFPI function; 3, enhances fibrin polymerization; and 4, 
accelerates factor XI back-activation by thrombin. (B) Short chained platelet-sized polyP acts most potently at 3 
points in the clotting cascade, indicated in red: 2 accelerates factor V activation and abrogated TFPI function; 3, 
overlaps the minimal size necessary to enhance fibrin polymerization; and 4, accelerates factor XI back-
activation by thrombin (Morrissey, Blood 2012).  
  
The role of polyPs in mammalian systems is rapidly emerging although to date, most studies 
have been done on polyPs from prokaryotes and unicellular eukaryotes. Interest in polyPs in 
human cells started with its detection in dense granules of platelets, which suggested a potential 
role in coagulation. Now it is recognized that polyP plays a role in several hemostatic and 
thrombotic mechanisms. PolyP acts at several steps in the coagulation cascade that influence 
thrombin generation; it enhances the generation of FXIa, [247] , accelerates the activation of 
FV to FVa by both FXa and thrombin [248], and it opposes the anticoagulant function of TFPI 
[249] (Figure 7). PolyP also influences fibrin clot structure and inhibits fibrinolysis [250]. Clots 
formed in the presence of polyP are more turbid, contain thicker fibrin fibers, are more resistant 
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to elastic stretching and are more resistant to fibrinolysis [251]. The mechanisms behind this 
are not known, but one possible explanation is that polyPs are incorporated in to the clots [246].  
In addition, PolyPs enhances the binding of platelets to von Willebrand Factor (VWF) which 
promotes platelet aggregation [252]. This has led to the consideration of polyphosphate as a 
potential target to prevent thrombosis [253, 254]. 
 
Bacterial long chained (LC-) polyPs (>200 units) are recognized as a surface for assembly of 
the coagulation proteins necessary for activation of the contact pathway of coagulation [43]. 
Studies have shown that LC-polyP is a potent trigger of the contact pathway [255, 
256]. Although LC-polyPs clearly activate coagulation through the contact pathway via FXII, 
the role of platelet-sized polyPs in FXII activation are less clear. 
 
Smith et al. showed that short-chained (SC-) polyPs from platelets modulated blood 
coagulation and fibrinolysis [255]. This was confirmed by the finding that platelet-derived 
polyPs were strong activators of the contact pathway through activation of FXII [7] in plasma. 
In addition, platelet-derived polyP triggered FXII activation in vivo, as its injection induced 
fatal pulmonary embolism and increased vascular permeability in wild-type mice, but not in 
FXII-deficient mice. These findings provide a plausible explanation for the bleeding diathesis 
in patients with Hermansky-Pudlak syndrome, whose platelets are deficient in dense granules 
and contain lower concentrations of polyP than normal platelets [257]. Despite these 
observations, however, it remained unclear if platelet polyP does activate FXII. LC-polyP has 
been proven to be a more potent activator of FXII compared to SC-polyP [256]. Faxälv et al. 
found that high concentrations of SC-polyP gave a weak and not physiologically relevant 
FXIIa generation compared to equal amount of kaolin in plasma. In addition, SC-polyP did 
not shorten clotting time in recalcified human whole blood. They conclude that platelet-
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derived polyPs do not activate the contact pathway via FXII, but might still play an important 
role in other steps of the cascade [258]. Recently, it was proposed that platelet polyPs are 
mobilized on the platelet surface, and activate the contact system by forming nanoparticles on 
the platelet surface [259]. The diverging results in the studies done on SC-polyPs and 
coagulation activation are difficult to explain and more studies are needed.  
 
Interestingly, polyPs have been shown to inhibit the complement system. In an experimental 
system with 2% serum monitoring complement activation by erythrocyte lysis, Wat at al. 
showed that polyP inhibited complement activation by blocking the C5 from assembling to 
the C5b-9 complex. The authors showed that both platelet sized and long-chained polyP had 
an inhibitory effect on the formation of the TCC, though the long-chained polyP showed a 
stronger effect than the platelet-sized [260]. In addition, Wijeyewickrema and colleagues 
found that SC-polyP acts as a cofactor for the C1 inhibitor. In the presence of SC-polyP 
together with C1-INH, C1s cleavage of C4 decreased [261] compared to the situation without 
polyPs. The inhibitory effect of SC-polyPs on the complement system are in contrast to the 
fact that the coagulation- and complement system act together. One explanation of these 
observations might be due to the experimental systems used. Both of the studies presented 
above used artificial systems to investigate the effect of polyPs on the complement system.  
Purified systems, such as buffer systems lack a number of regulatory proteins that will 
influence on the crosstalk in vivo.  
 
Since polyPs have been found to be involved in both the coagulation- and the complement 
system it is interesting to study them in light of VTE. If SC-polyPs from platelets modulate 
both systems they might be involved in the pathogenesis of VTE. FXII has been proposed as a 
target for VTE prevention. To date no studies on SC-polyP effect on FXII activation or on the 
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possible inhibitory effect on the complement system in whole blood have been conducted. 
Such studies would give us insight in to the effect of SC-polyPs on coagulation and 











































2. Aims of the thesis  
 
The aims of the PhD project were:  
1. To investigate the relation between the activation potential of the three complement 
pathways, and to explore their impact on VTE risk and thrombin generation in a 
population-based case-control study.  
 
2. To investigate whether total complement activation, assessed by plasma levels of the 
terminal complement complex (TCC), is associated with risk of VTE in a nested case-
control study. Moreover, to explore whether genetic variants were associated with 
plasma levels of TCC and investigate whether identified gene variants (if present) 
were associated with risk of VTE. 
 
 
3. To study the impact of exogenously added short chained polyphosphates (SC-polyP) 
on complement- and coagulation activations and explore underlying mechanism(s) in 




3. Methods   
  
3.1 Study population  
 
3.1.1 The Tromsø Study  
 
The Tromsø Study is a single center, population-based cohort study with repeated health 
surveys of the inhabitants of the municipality of Tromsø. The first survey was conducted in 
1974. To date, seven surveys have been conducted, with the last (Tromsø 7) conducted in 
2015/16. The primary aim of the Tromsø Study was to determine factors related to the high 
cardiovascular mortality observed in the northern part of Norway.  
 
In Tromsø 4, all inhabitants of the municipality of Tromsø aged ≥25 years were invited to the 
first screening visit, and 27158 participated (77% of the eligible population). The participants 
were followed from the date of inclusion (1994/95) until September 1, 2007, and all VTE 
events occurring among the participants in this cohort were registered. Participants were 
censored from the cohort at the date of death or migration from the Tromsø municipality. This 
cohort formed the basis for the case-control studies conducted in paper I and II of this thesis. 
 
In paper I, we conducted a case-control study of patients with unprovoked VTE and healthy 
controls. Cases and controls were screened and included in the study between April and 
September 2008. We identified VTE cases from Tromsø 4 who were still alive, were between 
20-80 years of age, and had experienced an unprovoked VTE 1-6 years ago. Twenty-eight 
cases were invited for a screening visit, and 24 of them were included in the study. For each 
case, one age- and sex-matched healthy control was randomly sampled from Tromsø 4. Thus, 
the final case-control study consisted of 24 patients with unprovoked VTE and 24 age- and 
sex-matched controls recruited from the general population. The study was approved by the 
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research ethics committee and all subjects gave informed written consent (REK Nord 
114/2007).  
 
In Paper II, we performed a nested case-control with cases and controls recruited from the 
fourth Tromsø Study. During follow-up (1994/95 through September 1, 2007), 462 
participants experienced a VTE event. For each case, two age- and sex-matched controls 
(n=924) were randomly sampled from the parent cohort. The index date for the controls were 
the time of VTE event for the corresponding case, meaning that the controls had to be alive 
and without a VTE-diagnosis at the time of inclusion.  In total, 47 cases and 76 controls did 
not have available plasma samples of sufficient quality for the TCC analyses, and the final 
study population consisted of 415 cases and 848 controls.  
 
Baseline measurements from the fourth Tromsø Study was collected by self-administered 
questionnaires, non-fasting blood samples and physical examinations performed by trained 
personnel. Height and weight were measured with the participants in light clothing without 
shoes. Body mass index (BMI) was calculated as the weight in kilograms divided by the 
square of height in meters (kg/m2). Waist circumference was measured in centimeters at the 
umbilical line. Blood pressure was recorded in the seated position by the use of an automatic 
device (Dinamap Vital Signs Monitor). Three recordings were made at 1-minute intervals, 
and the mean of the two last values was used in this report. Hypertension was defined as self-
reported use of antihypertensive medication or systolic pressure above 160 mmHg and/or 
diastolic pressure greater than 95 mmHg. Screening for factor V Leiden and prothrombin  





3.1.2 Outcome measurements and validation 
The University Hospital of North Norway (UNN) is the only hospital serving the region, and 
all diagnostic radiology and hospital care for VTE in the Tromsø region is provided by this 
hospital. The discharge registry covers both hospitalizations and outpatient clinic visits.  
All VTE events during follow-up were identified by screening the hospital discharge diagnosis 
registry, the autopsy registry and the radiology procedure registry at the University Hospital of 
North Norway (UNN). International Classification of Diseases (ICD)-codes were used to 
identify VTE events. Trained personnel reviewed the patients’ medical records to validate each 
potential VTE event. For a VTE to be recorded all the following criteria had to be fulfilled: 1) 
the presence of  signs and symptoms of a DVT or PE or both, 2) objective confirmation by  an 
objective diagnostic procedure (i.e. compression ultrasonography, venography, spiral computed 
tomography, perfusion-ventilation scan, pulmonary angiography or autopsy), 3) diagnosis of a 
DVT or PE noted by a physician in the medical record, 4) initiation of VTE treatment (i.e. 
anticoagulant treatment, thrombolysis) unless contraindications were specified. Potential VTE 
cases derived from the autopsy registry were adjudicated and recorded when the autopsy report 
indicated VTE as the cause of death or as a significant condition associated with the cause of 
death.  
VTE events were classified as DVT or PE and if they occurred simultaneously they were 
classified as a PE. VTEs were also classified as provoked or unprovoked based on the presence 
or absence of provoking factors at the time of diagnosis. Provoking factors were recent surgery 
or trauma, acute medical conditions, active cancer, immobilization (bedrest > 3 days, 





3.2 The whole blood model  
 
The whole blood model was initially developed by T.E. Mollnes [262], and has since then 
been used in a wide range of studies. The model uses whole blood anticoagulated with 
lepirudin, which makes it suitable to study complement and coagulation activation 
simultaneously, in vitro. Lepirudin is a hirudin analogue, which directly inhibits thrombin and 
thus the coagulation cascade is kept functional upstream of thrombin formation which enables 
us to study the initiation phase and activation of coagulation. The blockage of thrombin also 
enabled us to isolate the effect of polyPs on FXII activation, without the positive feedback 
activation from thrombin. Furthermore, lepirudin has no adverse effects on complement 
activation and we can study total complement activation. Anticoagulants containing calcium 
chelators (eg, EDTA and citrate) inhibit complement activation as well as a number of other 
plasma and cell inflammation markers and therefore cannot be applied in a whole blood 
system investigating complement. Heparin has been shown to activate or inhibit the 
complement system depending on the dose used [262, 263].  
 
We conducted experimental studies using the human whole blood model. Human whole blood 
from healthy fasting donors was used to study cellular interactions and molecular mechanisms 
for the interplay between SC-polyP and complement- and coagulation-activation. The study 
was approved by the national ethics committee and all participants gave written informed 









3.3 Laboratory measurements  
 
In paper I, TF-induced thrombin generation was assessed in plasma using Calibrated Automated 
Thrombinoscope (CAT) and was performed as described by Hemker et al [264] and according 
to the manufacturer’s instructions (Thrombinoscope BV, Maastricht, the Netherlands). 
Thrombin generation was measured in a Fluoroscan Ascent Fluorometer (Thermolabsystems 
OY, Vantaa, Finland) equipped with a dispenser. Fluorescence intensity was detected at 
wavelengths of 355 nm (excitation filter) and 460 nm (emission filter). Briefly, 80 µl of the 
plasma samples were dispensed into the wells of round bottom 96-well microtiter plates 
(Immulon, Lab Consult, Lillestrøm, Norway). Twenty µl of a mixture containing TF (Innovin, 
Bade Behring) and phospholipids (PL) (Cephaline, from rabbit brain) was added to the plasma 
samples to obtain a final concentration of 5 pM and 4 µM, respectively. For each experiment, 
a fresh mixture of 2.5 mM fluorogenic substrate (Z-Gly-Gly-Arg-AMC from Bachem, 
Bubendorf, Switzerland) and 0.1 M CaCl2 was prepared using buffer containing 20 mM Hepes 
(Sigma Aldrich, St Louis, USA) and 60 mg/ml BSA (A-7030, Sigma Aldrich) with pH 7.35. 
The calibrator with thrombin activity of 600 nM was obtained from Thrombinoscope BV 
(Maastricht, The Netherlands). The thrombin calibrator corrects for donor-to-donor differences 
in color of plasma and inner filter effect [265]. The computer software calculated lag time (min), 
the time to peak (min), the peak of thrombin generation (nM) and the area under the thrombin 
generation curve (nM*min) or endogenous thrombin potential (ETP).  
 
Measurements of white blood cells, platelets and hemoglobin were performed with the ABX 





In paper I, the potential activity of the classical, alternative, and lectin pathways of the 
complement system was assessed by a commercially available assay (Wielisa COMPL300 
Total Complement Functional Screen kit from Wieslab AB, Lund, Sweden) and conducted 
according to the instructions provided in the manual. In brief, strips of wells for classical 
pathway (CP) evaluation were pre-coated with IgM, strips for alternative pathway (AP) 
determination were coated with LPS, and lectin pathway (LP) strips were coated with mannan. 
Sera were diluted in specific buffers (1/101 for the CP and LP assays, and 1/18 for the AP 
assay), and were incubated for 1 h at 37°C. After washing the strips, alkaline phosphatase-
conjugated antihuman C5b-9 was added before incubation at room temperature for 30 min. 
Additional washing was performed, substrate was added, and the wells were incubated for 30 
min. Finally, absorbance values were read at 405nm.  
 
In each assay, standard positive and negative control serum provided in the kit were 
reconstituted with distilled water. The positive serum was a pool of five sera from healthy 
individuals, and the negative control consisted of heat-inactivated sera (56°C for 20 min). 
Complement activity was calculated using the following formula:  
Activity = mean A405 (sample)−mean A405 (negative control)
mean A405 (standard serum)−mean A405 (negative control)
100% 
Samples as well as standard serum and negative control serum were tested in duplicates at a 
fixed dilution. All complement activity values are provided as % of activity in pooled normal 
serum. The assay is designed as a screening assay to detect deficiencies in the various 
complement pathways. It is not suitable to detect in vivo activation, but reflects the total activity 




In paper I, measurement of serum concentrations of MBL was performed using an MBL 
enzyme-linked immunosorbent assay (ELISA) kit (BIOPORTO Diagnostics A/S, Hellerup, 
Denmark) according to the manufacturer’s instructions.  
 
In paper II and III, plasma levels of TCC were measured using an in-house enzyme-linked 
immunosorbent assay (ELISA) as described previously [267]. In brief, ELISA plates (Nunc, 
Immunoplate II, Copenhagen, Denmark) were coated with the monoclonal antibody, aE11 
specific for a neoantigen exposed in C9 after activation and incorporation into TCC, the poly 
(C9) unit of the TCC. Biotinylated anti-C6 monoclonal antibody (9C4) was used as detection 
antibody and Streptavidin horseradish peroxidase (GE Healtcare UK) was added as the final 
step. Optical density was measured at 405 nm (Dynatech MR580, Dynatech Laboratories Inc., 
Alexandria, Va., USA). Results are given in Complement Arbitrary Units (CAU)/mL. 
 
In paper III, prothrombin fragment 1+2 (F1+2) was measured by enzyme-linked 
immunosorbent assay kit (Siemens, Enzygnost ® F 1+2 MONO, Marburg, Germany) 
according to the manufacturer’s instructions. In short, thawed plasma was added to a 96 well 
plate and incubated for 30 minutes before addition of anti-human prothrombin monoclonal 
mouse antibody. After 15 minutes of incubation, the substrate Tetramethyl benzidine 
dihydrochloride (TMB) was added and incubated for 15 minutes. After addition of the 
stopping solution, the plate was read at 450nm with a reference wavelength of 650nm nm 
(Dynatech MR580, Dynatech Laboratories Inc., Alexandria, Va., USA). The standard curve 
was created by reading the wavelength of standard 1-4 with known concentrations, supplied 





3.4 Statistical analyses 
 
All statistical analyses were conducted in SPSS for Windows, version 22.0 (SPSS Inc. 
Chicago, Illinois, USA), GraphPad Prism version 5.04 for Windows (GraphPad Software, San 
Diego, California, USA) or R version 3.4.4.  (The R Foundation for Statistical Computing c/o 
Institute for Statistics and Mathematics, Wien, Austria). 
 
 
In Paper I, Spearman nonparametric correlation coefficient was used to test for correlations 
between variables. For complement pathway activity data and parameters of the thrombogram, 
between-group differences for these variables were tested with independent samples t-test. 
Logistic regression models were used to determine the predictive role of complement pathway 
activity and thrombogram parameters for VTE.  
 
In Paper II, TCC was categorized according quartile cutoffs in the control population (≤0.80, 
0.80-1.04, 1.04-1.40, >1.40 CAU/ml). Means and proportions of baseline characteristics 
across quartiles of TCC were calculated using descriptive statistics. Logistic regression 
models were used to calculate odds ratios (ORs) of VTE with 95% confidence intervals (CI) 
according to quartiles of TCC. The lowest TCC quartile was used as the reference group. We 
also calculated the p-value for linear trend in OR across increasing quartiles of TCC.  
 
In Paper III, differences between the samples were tested with Student`s t-test. For non-





4. Summary of papers  
 
4.1 Paper I  
 
IMPACT OF COMPLEMENT PATHWAYS ACTIVITY, MANNOSE-BINDING LECTIN 
AND TISSUE-FACTOR INDUCED THROMBIN GENERATION ON THE RISK OF 
UNPROVOKED VENOUS THROMBOEMBOLISM 
 
Deep vein thrombosis (DVT) originates in the valvular sinuses of large veins in a local milieu 
characterized by stasis and severe hypoxia. This may induce complement- and coagulation 
activation, which potentially increases the risk of venous thromboembolism (VTE). We 
wanted to investigate whether the activity of the complement pathways, the level of mannose-
binding lectin (MBL) and tissue-factor (TF) induced thrombin generation were associated 
with risk of unprovoked VTE. We performed a case-control study in patients with 
unprovoked VTE (n=24) and age- and sex-matched healthy controls (n=24).  Serum 
complement pathway activity was measured by the total complement screen assay 
(Wieslab®). MBL was quantified by ELISA. Plasma TF-induced thrombin generation was 
measured using the CAT-assay. We found that activity in the highest quintile of the classical 
pathway was associated with increased odds of unprovoked VTE (OR 4.5, 95% CI; 0.8-24.7). 
Moreover, MBL deficiency (≤100 ng/ml) was associated with unprovoked VTE (OR 3.5, 95% 
Cl; 0.8-15.3). VTE patients had shortened TF-induced lag-time (4.8±0.6 min vs. 5.8±2.1 min, 
p<0.001) and a higher endogenous thrombin potential (ETP) (1383±267 nM*h vs. 1265±247 
nM*h, p=0.07) than controls. No association between the classical complement pathway 
activity or MBL deficiency, and parameters of TF-induced thrombin generation was observed.  
These results suggest that high activity of the classical complement pathway, and MBL 





4.2 Paper II 
 
COMPLEMENT ACTIVATION ASSESSED BY TERMINAL COMPLEMENT COMPLEX 
AND FUTURE RISK OF VENOUS THROMBOEMBOLISM 
 
Growing evidence support a link between key components of the complement system and risk 
of venous thromboembolism (VTE). However, it remains uncertain whether activation of the 
complement system, assessed by soluble terminal complement complex (plasma TCC), is 
associated with future risk of incident VTE. The aim was to investigate the association 
between plasma levels TCC and future risk of incident VTE in a nested case-control study and 
to explore genetic variants associated with plasma levels TCC using protein quantitative trait 
loci (pQTL) analysis of exome sequencing data. The study population consisted of 415 
subjects with VTE events and 848 age- and sex-matched controls who were selected from a 
population-based cohort, the Tromsø Study. Logistic regression models were used to calculate 
odds ratios (ORs) with 95% confidence intervals (CIs) for VTE across quartiles of plasma 
levels of TCC. Whole exome sequencing was conducted in 709 subjects (355 VTE patients 
and 354 control subjects) using the Agilent SureSelect 50Mb capture kit. The risk of VTE 
increased across quartiles of plasma TCC, particularly for unprovoked VTE (p for trend 0.02). 
Participants with plasma TCC in the highest quartile (> 1.40  CAU/mL) had an OR for 
unprovoked VTE of 1.74 (95% CI: 1.10-2.78) compared to those with plasma TCC in the 
lowest quartile (≤ 0.80 CAU/mL) in analyses adjusted for age, sex, body mass index. The OR 
for VTE by high plasma TCC was substantially higher in individuals with short time between 
blood sampling and VTE event. We found no significant association between genome-wide 
and complement-related gene variants and plasma TCC.  Our findings showed that plasma 
levels TCC are independent of gene regulation and that high levels of plasma TCC are 
associated with VTE risk and unprovoked events in particular. 
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4.3 Paper III  
 
THE EFFECT OF SHORT- CHAINED POLYPHOSPHATES ON 
COAGULATION AND COMPLEMENT ACTIVATION IN A HUMAN 
WHOLE BLOOD SYSTEM 
 
Polyphosphates (polyPs) are naturally occurring, highly anionic linear polymers of 
monophosphate units. Short-Chained (SC)-PolyPs are secreted from platelets upon 
stimulation and are reported to inhibit complement activation under experimental conditions 
and to facilitate propagation of coagulation activation. We aimed to investigate the impact of 
SC-polyPs on coagulation- and complement activation in a whole blood model. Blood was 
collected from healthy fasting individuals and anticoagulated with the thrombin inhibitor 
lepirudin. Blood was incubated with SC-polyPs (0-100 µM) and E.coli (107 CFU/ml). 
Complement activation was monitored by plasma terminal C5b-9 complement complex 
(TCC) and coagulation activation by prothrombin fragment 1+2 (F1+2) using ELISA assays.  
Infestin was used to block the coagulation activation product FXIIa, and the impact of tissue 
factor (TF) on coagulation activation was monitored by TF mRNA expression and use of 
blocking anti-TF antibodies. We found that SC-polyP in concentrations 40 and 100 µM 
promoted coagulation activation (p<0.01 compared to time-matched controls), but to a lesser 
extent than long-chained polyp in whole blood. E.coli induced a time-dependent (0-30 min) 
complement activation in whole blood (p<0.001), but SC-polyP did not modify this E.coli-
induced complement activation. Preincubation with the FXIIa-inhibitor infestin, completely 
blocked SC-polyP-induced coagulation activation (plasma F1+2: 1939±619pmol/l with 
100µM polyP vs. 578±285pmol/l with infestin and 100µM polyP; p<0.001) without affecting 
complement activation. In conclusion, SC-polyP triggered FXII-dependent coagulation 
activation without affecting complement activation in a whole blood model.  
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5. General discussion   
 
5.1 Methodological considerations   
 
5.1.1 Study design  
 
Paper I and II in this thesis utilize data from a large population-based cohort, the Tromsø 
Study. The Tromsø Study has a high attendance rate (77%) and all inhabitants ≥25 years were 
invited, which makes it a suitable cohort for studying the general population. Paper I has a 
case-control design, whereas paper II has a nested case-control study. 
 
Case-control studies are more efficient and less resource demanding than cohorts.  A case-
control study is an observational study that compares attributes of sampled cases and controls. 
However, most case-control studies are retrospective, and prone to reverse causation and 
recall bias, and can therefore not be used to assess cause-and-effect relationships. Paper I of 
this thesis is a case-control study where cases were derived from the fourth Tromsø Study and 
the controls were derived from the sixth Tromsø Study. The blood samples were drawn 1-6 
years after the VTE event, and thus it is not possible to assess if the increase in potential 
complement activation is a cause or a consequence of the VTE event. However, we only 
recruited cases with a VTE event >1 year before blood sampling to minimize the risk of 
reverse causation.  
 
Paper II in this thesis is a nested case-control study where all participants were sampled from 
the same parent cohort (i.e. the fourth Tromsø Study), and matched on age and sex. A nested-
case-control study enables us to limit the use of expensive analysis without sacrificing the 
temporal advantage of cohort studies. The blood samples were taken at inclusion in Tromsø 4 
(1994/95), frozen after blood collection, and thawed and analyzed several years later. In this 
study, we know that the increase in TCC in VTE cases is not due to the VTE since the blood 
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samples were taken before the event. This enables us to speculate in cause-and-effect specific 
relationships between TCC levels and VTE.   
 
5.1.2 Bias  
 
Bias is the term for systematic errors in epidemiological research that results in incorrect 
estimates of the true effect of an exposure on the outcome. Biases may be introduced into a 
study at different points and are divided into different types:  
 
Selection bias occurs when there is a systematic error in recruitment of study participants so 
that the association between exposure and outcome gets affected. This is less likely to occur 
in cohort studies, since both cases and controls are selected before the outcome occurs and 
many exposures and outcomes can be studied in one survey. There is, however a chance for a 
non-response bias in cohorts, where the responders are different from the non-responders 
[268]. In other designs, such as a case-control study, selection bias is more easily introduced.  
The controls have to be representative for the population from which the cases are derived 
with respect to the distribution of exposures and confounders. The likelihood of achieving this 
is higher if the cases and controls are recruited from the same predefined source population. 
The selection of controls may be biased since there is a risk of including controls that do not 
represent the source population of the cases. In paper I, we randomly sampled participants 
from the fourth Tromsø study and invited them to participate as controls in our study. In paper 
II, the controls were randomly sampled from Tromsø 4. In both studies, the controls were 
matched on age and sex to minimize the risk of selection bias. Moreover, in both papers I and 
II, the cases were derived from a well-defined cohort, and the diagnosis was thoroughly 




Misclassification bias can be non-differential or differential. A misclassification is non-
differential when it is independent of the outcome and similar across comparison groups. 
Non-differential misclassification most often leads to underestimation of the true association. 
Studies including baseline information obtained through self-administered questionnaires are 
vulnerable to misclassification as participants may report their exposure levels incorrectly. 
Moreover, random errors in biological measurements may lead to misclassification. 
Regression dilution bias is an example of non-differential misclassification. The regression 
model assumes that variables like smoking habits, cholesterol levels, and dietary habits stay 
the same throughout the study period. If the variable changes during the follow-up, and this is 
not corrected for in the analysis, it might lead to a dilution of the true effect [269, 270].  
Regression dilution bias can be introduced by true changes in the exposure variable, or by 
random measurement errors in the exposure variable, and leads to attenuated risk estimates 
[269].  In a cohort, where blood samples are taken before the outcome occurs and the 
exposure levels do not affect the outcome assessments, the misclassification of exposure is 
likely non-differential. Plasma levels of modifiable biomarkers are expected to change over 
time, [269] when there is a long follow up time.  Accordingly, in Paper II, we found that the 
risk of VTE by plasma levels of sTCC varied substantially over time between blood sampling 
and the VTE event, and this phenomenon was likely explained by regression dilution.  
 
Misclassifications are differential if the misclassification is dependent on the value of an 
exposure. Differential misclassifications can introduce biases in either direction [269]. In 
case-control studies, with measurements collected after the cases and controls are chosen, 
there is a potential for differential misclassification. This might be due to recall-bias, which 
implies that the cases and the controls might recall their medical history differently, and 
describes the tendency for cases to recall an exposure more often that controls [271]. 
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Differential misclassification can also occur in prospective studies if the outcome 
assessment/adjudication is influenced by the known exposure levels (e.g. if a participant is 
more likely to be referred to screening for an event due to his/her risk factor level). In paper I 
the VTE events were symptomatic, objectively confirmed by radiological procedures and 
adjudicated by persons who were blinded for the measurements of potential complement 
activation, which diminishes the possibility of differential misclassification.  
 
5.1.3 Missing data  
 
Missing data is common in medical research, and it is not possible to eliminate the possibility 
of missing data completely. Missing data can be introduced when participants do not respond 
to questions in a questionnaire, if equipment fails, procedures are not followed, by loss or 
errors in laboratory handling of samples, or any other reason that leads to loss of data [272]. 
Careful handling and execution of studies are important to reduce this problem. However, 
there is no optimal approach to ensure avoidance of missing data. If the number of missing 
data of one variable is very high, the variable should be excluded from the study. If the 
number of missing data of one variable is low, the subjects with missing values can be 
excluded [272]. If those with missing data differ from those with complete data, exclusion 
might lead to selection bias. In addition, exclusion of subjects will reduce the statistical 
power. To maintain sample size, and thus the statistical power, one can replace missing data. 
Imputation (i.e. replacement), can be used if the missing values are missing at random, if the 
data is not missing at random one can use multiple imputations [272].  In paper II, we 
excluded 47 (10%) cases and 76 (8%) controls due unavailable plasma samples of sufficient 
quality for the analyses. Since the proportion of missing was low, and likely non-differential 
(i.e. the chance of having an insufficient blood sample would not depend on the outcome), 




A study has high external validity if the results are applicable to the whole source population, 
and to similar populations (i.e. the study has high generalizability). The age and sex 
distribution of the Tromsø population is comparable to other Western populations [273]. The 
incidence and prevalence of cardiovascular diseases, traditional cardiovascular risk factors 
and the incidence of VTE and cancer is comparable to the incidence found in other studies of 
similar populations [273, 274]. The high attendance rate (77% of those invited) suggest that 
the Tromsø Study has high external validity.  
 
5.1.4 Sample size and statistical power  
 
The power of a study describes how likely it is to find an effect if present. Statistical power is 
affected by the size of the effect (effect size) and the size of the sample used to detect it. 
Bigger effects are easier to detect than smaller effects, while large samples offer greater test 
sensitivity than small samples. The statistical power can be increased by increasing the 
sample size [275]. The probability of making a type II error i.e. concluding that there is no 
effect when there is one is low when the statistical power is high. Power calculations should 
be done when planning a study and it is common to aim towards 80% power, which means 
that there is an 80% probability that a type II error will not occur. The acceptable probability 
of making a type I error i.e. to find and effect when there is none, is in most cases set to 5%.  
 
In a case-control the statistical power in mainly determined by the number of cases you have, 
but can be increased by including more than one control per case [276]. However, in subgroup 
analysis, the number of outcomes in each group can be small, and subgroup analysis can have 
less power than the main analysis. To calculate the sample size before a study is conducted, 
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assumptions on expected effect have to be made. These assumptions are often made based on 
previous knowledge and studies in the field.  
 
It is a challenge to calculate sample size in experimental studies, as we in most cases do not 
know the outcome of the study. In paper III, we could not estimate the effect on polyP on 
coagulation- and complement activation in our whole blood model since it had never been 
done before.  
 
5.1.5 The whole blood model  
 
Using the human whole blood model in paper III makes the experimental system more 
physiological relevant than using buffer, plasma, or serum models. We can model the result of 
the influence of known agents such as polyP, but also take in to account the influence of other 
factors residing in the blood. Although the complexity of whole blood reduces our ability to 
provide exact mechanisms for the effect, it allows us to evaluate the effect of interventions 




Figure 8. The effect of SC-polyP in our 
whole blood model where thrombin is 
blocked. The potentiation effect on 
coagulation activation of SC-polyP 
through thrombin are blocked, leaving us 
with the isolated effect of SC-polyP on 
FXII activation (adapted from Morrissey, 




There are important limitations to consider when using the whole blood model. The model 
represents an intermediate between in vitro and in vivo experiments, and although the 
complexity of the blood is preserved there are still processes and reactions, which are lost 
when removing it from the endothelial lining of the vessels. The fact that whole blood has to 
be anticoagulated is also a limitation as it interferes with the natural processes in the blood. 
Lepirudin was the most suitable anticoagulant in our experiment since it does not interfere 
with complement activation or Ca2+ levels and enables us to study the coagulation system 
upstream of thrombin. However, as mentioned previously, thrombin might be an important 
player in the crosstalk between complement- and coagulation activation, and we lose this 
possible interaction between the systems. On the other hand, the use of lepirudin is 
advantageous when studying polyP’s effect on coagulation activation, since it makes it 
possible to isolate the possible effect of polyPs on FXII activation, without the positive 





5.2 Discussion of main results  
 
5.2.1 High potential activity in the classical pathway of the complement system and MBL 
deficiency is associated with increased odds for unprovoked VTE (paper I) 
 
In paper I, we found that subjects with potential activity levels within the highest quintile of 
the classical pathway had a higher risk of unprovoked VTE.  Moreover, MBL deficiency and 
low lectin pathway activity, was associated with increased risk of VTE.  
 
We recruited VTE patients from a population-based cohort and age- and sex-matched 
apparently healthy controls from the same source population, making it a representative study 
population for the general population. To study complement activity we used an assay designed 
as a screening assay to detect deficiencies in the complement pathways. It is not suitable to 
detect in vivo activation, but reflects the total activity potential within each complement 
pathway by in vitro activation [266]. The pathway activity was measured as a percentage of a 
standard pathway activity derived from normal human serum, defined to contain 100% activity 
in all three pathways. The percentage of normal pathway activity was used to assess if the 
potential activity of the complement pathways showed different risk estimates for VTE. The 
use of this method is a novel approach to study the association between complement pathways 
and diseases. However, the results should be considered as exploratory since these 
measurements represent the potential for activation and not activation in vivo.   
 
The classical pathway of the complement system and risk of VTE has been studied in systemic 
lupus erythematosus (SLE) patients. In a Swedish study, SLE patients with a history of VTE 
had increased deposition of C1q, C3, and C4d on platelets compared to SLE patients without 
VTE [245], indicating classical pathway activation. Accordingly, we found an OR of 4.5 for 
the association between high potential serum activity of the classical pathway and unprovoked 
VTE in a study with participants from the general population. As thrombin is known to activate 
63 
 
complement component C3 [219], one possible explanation for the association between high 
potential complement activity and VTE could be hypercoagulability. We investigated this 
possibility by measuring thrombin generation in plasma by Calibrated Automated 
Thrombogram (CAT). We found that high potential activity of the classical complement 
pathway was not associated with parameters of TF-induced thrombin generation. This indicated 
that the association between high potential activity of the classical pathway of the complement 
cascade and VTE risk was independent of coagulation parameters. One possible mechanism for 
the association between high activity of the classical pathway of the complement system and 
VTE risk might be the hypoxic state found in the veins, particularly in the deepest recess of the 
valvular sinus, where the thrombus forms [1, 38]. Hypoxia has been found to activate the 
complement system [277] and re-oxygenation of hypoxic HUVEC cells incubated with 30% 
serum leads to activation of the classical pathway [278]. It is reasonable to think that the 
hypoxic state in the valvular sinuses leads to activation of the complement system, which again 
can initiate thrombus formation.   
 
Between 5-20% of the population is estimated to be MBL-deficient [279, 280]. Samples that 
were low in the lectin pathway activity assay, were therefore quantified for MBL 
concentration in a separate ELISA to ensure that subjects did not have a MASP deficiency. 
Even though >99% of the lack of lectin pathway activity is due to MBL deficiency, 
occasionally MASP-2 deficiency has been found, of which one case is reported in Norway 
[281]. MBL levels have been found to remain stable throughout life, making it a good 
candidate as biomarker for various diseases. Age, gender, and diurnal variation do not affect 
MBL levels of an individual, and there is only a mild increase during acute phase reactions 
[282]. Individuals with MBL levels below 100ng/ml have high prevalence of associated 
diseases [279, 283]. MBL-deficient individuals have increased susceptibility to various types 
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of infectious disease, as well as several noninfectious disorders, including autoimmune 
disorders [284-286].  In addition, the lectin pathway MBL associated serine protease-1 
(MASP-1) has been shown to be a significant contributor to coagulation in a mouse model 
with occlusive thrombosis [286], and have thrombin-like properties [287, 288].  Based on this 
we suggested that MBL deficiency would be protective against VTE. Prior to our study, two 
smaller studies had investigated the association between genotypes associated with MBL 
deficiency and risk of VTE in patients with SLE. One study found that VTE in SLE patients 
were unrelated to the MBL genotype [278].  However, in a cross-sectional study including 
114 SLE patients, the prevalence of VTE was higher in subjects with MBL-deficient 
genotypes [279]. In our case-control study, VTE patients had 3.5-fold higher odds of MBL 
deficiency (≤100 ng/ml) than controls. The MBL levels were strongly correlated with 
potential lectin pathway activity, and similarly to MBL levels, low lectin pathway activity 
showed a trend towards an increased risk of VTE. The underlying mechanisms for the 
possible association between MBL deficiency and VTE risk is not obvious, but may be a 
consequence of the predisposition to autoimmune- [280, 281] and infectious disease [282, 
283], in individuals with MBL deficiencies, both of which are associated with the risk of VTE 
[284, 285].  
 
 
Traditional case-control studies are retrospective in nature, meaning that blood samples are 
often drawn after the event of interest.  In our study, blood samples were drawn 1-6 years 
after the VTE event. Thus, it is not possible to determine whether increased complement 
pathway activity was present before the event or was a consequence of the VTE event 
(reverse causation). However, the rather long time between the VTE event and blood 
sampling strengthened the probability of that the increased complement activities were 
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present prior to the event and not an acute reaction of the VTE event. Due to the low number 
of participants included in this study the risk of statistical type 1 and 2 errors are considerably 
increased. Statistical analysis of such a small sample size has limitations, and the results 
should be interpreted with caution. Thus, a larger, prospective study should be conducted to 
validate these findings.  
 
5.2.2 Complement activation assessed by TCC is associated with future risk of VTE 
(paper II) 
 
In Paper II, we investigated the association between complement activation, assessed by 
plasma levels of TCC, and future risk of VTE in a population-based nested case-control study. 
The risk of all VTE, and especially unprovoked VTE, increased across quartiles of plasma 
TCC. Subjects with plasma TCC in the highest quartile had 74% higher risk of unprovoked 
VTE compared to those with plasma TCC in the lowest quartile. Furthermore, we found no 
significant association between genome-wide and complement-related gene variants and 
plasma levels of TCC.  
 
Prior to our study, no study had investigated complement activation assessed by plasma TCC 
and risk of VTE. The studies done on complement and VTE risk were restricted to animal 
models, with the exception of one large population-based cohort (the Copenhagen General 
Population Study).  In the latter study, subjects with plasma C3 levels in the highest tertile had 
31% higher risk of VTE after adjustment for CRP and BMI [243]. This study investigated the 
association between plasma levels of C3 and future risk of VTE and not the activation of the 
complement system. This led to the question of whether C3 was a mediator of VTE risk or 
merely an innocent bystander. The impact of C3 on VTE risk has also been investigated in an 
animal model. C3-deficient mice had lower incidence of venous thrombosis and reduced 
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thrombus size compared to wild-type mice [287]. The pivotal role of C3 in complement 
activation [243] may suggest that complement activation drives the observed link between C3 
and VTE risk. To investigate this we measured the end stage of complement activation, 
namely the formation of the terminal TCC complex C5b-9, also called the membrane attack 
complex (MAC) when assembled on a membrane. If the terminal pathway is activated in the 
fluid phase, the TCC complex will build up in a soluble form (plasma TCC), that can be 
measured in plasma as an indicator of complement activation. We found that plasma TCC was 
associated with increased risk of VTE, and especially unprovoked VTE. This indicates that it 
is activation of the complement system that is associated with VTE risk, and the observed 
association between C3 and VTE is due to complement activation.  
 
Several studies has found that the dysregulation of the complement system is associated with 
different arterial and cardiac diseases [289-291]. Depositions of the TCC [292, 293] and other 
complement components have been found in human infarcted myocardium [294]. It was 
previously shown that re-oxygenation of hypoxic human endothelial cells leads to activation 
of the complement system via the classical pathway [278]. As discussed for the classical 
pathway and VTE risk, the hypoxic state found in the deepest recess of the valvular sinus, 
where the thrombus forms [1, 38] may also activate the complement system [277, 295] and 
potentiate thrombus formation. This may be part of the explanation of why complement 
activation is associated with VTE risk.  Moreover, in our study, genome-wide and 
complement-related gene variants showed no significant association with levels of plasma 
TCC. This strongly suggests that plasma TCC is determined by environmental rather than 
genetic factors. Subjects susceptible to future VTE may exhibit a certain pathophysiological 
milieu in the valvular sinuses, which makes them prone to complement activation and thereby 
future risk of VTE, or have dysregulation of the complement system in these locations. This 
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further supports the results from paper I where we found that high potential classical pathway 
activity of complement was associated with higher risk of VTE, independent of TF-induced 
thrombin generation.  
 
It is not only the location of thrombus formation which may explain the effect of complement 
activation on VTE risk.  Evidence supports that complement activation is a mediator of VTE 
risk through platelet- and coagulation activation. If the TCC is incorporated in the cell 
membrane of platelets, it results in the exposure of negatively charged phosphatidylserine 
(PS) on the activated platelet surface [290] that may assemble and amplify coagulation 
reactions [291]. It can also lead to the formation of procoagulant microvesicles (MVs) [211], 
which is associated with risk of VTE [145], and secretion of procoagulant granules from the 
cytoplasm of platelets [212].  In addition, the complement system has direct procoagulant 
activities, including the ability to cleave and activate coagulation factors [214] and increase 
TF expression in various cell types [214, 215].  
 
This study was a nested-case-control study and the blood samples were obtained at inclusion 
in Tromsø 4 (1994/95), and analyzed several years later. The time sequence between exposure 
(high plasma TCC) and outcome (VTE) makes it possible to speculate about a potential causal 
relationships between plasma TCC levels and VTE risk. As plasma levels of TCC are 
modifiable and will fluctuate over time, the association to VTE risk is likely to be 
underestimated in our study with long follow-up time (regression dilution bias). To address 
the possibility of regression dilution bias we performed statistical analysis where we restricted 
the maximum time from blood sampling to the VTE events. Consequently, we found that the 
risk of VTE by plasma TCC was higher with shorter time between blood sampling and VTE. 
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This indicates that the true association between plasma levels of TCC and VTE risk is 
stronger than found in our study with long follow-up.  
 
Similar to the results from paper I, the risk of VTE is higher in subjects with high activation 
of the complement system. We can assume that the complement system is involved in the 
pathogenesis of VTE based on the results from previous studies and our results on 
complement activation and VTE risk. Functional studies are needed to investigate the 
molecular mechanisms behind the association between plasma TCC and VTE risk.  
 
5.2.3 The role of polyphosphates in coagulation and complement activation (paper III) 
 
 
In paper III, we investigated the effect of short chained (SC) polyphosphates (polyP) on 
coagulation- and complement activation in a human whole blood model where thrombin was 
blocked. We found that SC-polyP significantly increased prothrombin fragment 1+2 (F1+2) 
levels in whole blood after 60 minutes, indicating that it activates the coagulation system. 
Inhibition of FXIIa abolished the SC-PolyP induced coagulation activation, showing that SC-
polyP plays a role in initiating activation of the contact pathway of coagulation. We found 
that SC-polyP did not influence E.coli-induced TCC formation in whole blood.  
 
No studies had investigated the direct effect of platelet-sized polyPs on coagulation activation 
in whole blood where the Ca2+ concentrations are kept physiological. Our whole blood model 
takes advantage of the fact that thrombin is blocked. This enables us to investigate the isolated 
effect of SC-polyPs on FXII activation. To the best of our knowledge, no such investigations 
of SC-polyPs had previously been performed in a whole blood model with physiological Ca2+ 




For many years the true activators of the contact pathway were unknown and most of the 
studies done on contact activation used artificial surfaces. Platelet-sized polyPs where found 
to be an activator of the intrinsic pathway of coagulation through activation of factor FXII [7, 
255], and to bind tightly to the proteins responsible for contact activation [255, 256]. Clinical 
studies have shown that elevated levels of plasma FXII is associated with coronary heart 
disease and atherosclerosis [296, 297], and studies in mice showed that FXII deficiency 
protected against thrombosis [150]. In addition, cationic inhibitors of polyP reduced venous 
and arterial thrombosis in animal models [298] . This made platelet polyP an interesting 
molecule to study in the contact activation and in the pathogenesis of VTE. However, later 
studies showed that the ability to activate FXII in the absence of blood cells was dependent on 
polymer length [256, 258, 299], and now bacterial long-chained polyPs (>200 units) are 
recognized as a surface for assembly of the coagulation proteins necessary for activation of 
the contact pathway of coagulation [43]. Nowadays, SC-polyP is thought to be involved in 
acceleration of coagulation activation and not in the initiation [300]. Contrary to this, we 
found that SC-polyP significantly increased plasma levels of F1+2 in human whole blood 
after 60 minutes, and that this effect was abolished when pre-incubating blood with the FXIIa 
specific inhibitor infestin. This indicates that SC-polyPs activate FXII in human whole blood. 
This was further proved by the fact that tissue factor (TF)-mRNA levels in blood incubated 
with SC-polyPs were not elevated and we did not observe any effect of anti-TF antibody on 
SC- polyP induced coagulation activation.  
 
Over the past decades, several studies have reported that activated platelets promote 
coagulation in a FXII-dependent manner [301-304]. Indeed, the presence of platelets in our 
whole blood model might explain why SC-polyP could activate FXII, but not by others that 
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used systems without platelets. Platelet-derived polyPs have been found to bind to and 
aggregate on the platelet surface and form nanoparticles that promote FXII activation [259]. 
The aggregation of polyPs on the platelets surface leads to a high local concentration of 
polyPs. Moreover, it is possible that there is a presence of longer chained polyPs on the 
platelet surface after activation [259]. In addition, polyPs have been found to bind to the 
platelet surface together with FXII [305]. These findings together with our results, which 
show that SC-polyPs activate FXII in whole blood, makes it reasonable to speculate that  the 
ability of SC-polyPs to activate FXII is dependent of the presence of platelets.  
 
When we started this work, only two studies had investigated the effect of polyPs on 
activation of the complement system. Wijeyewickrema and colleagues found that SC-polyP 
acted as a cofactor for C1 inhibitor (C1-INH), which is the major negative regulator of the 
classical- and lectin pathway. [261]. They found that polyP potentiated the inhibitory function 
of C1-INH, dampening complement activation [261]. Moreover, Wat and colleagues found 
that polyP suppressed the terminal pathway of complement by destabilizing the assembly of 
the TCC in a size and concentration dependent manner. They found that P1 and 
polyP>1000 suppressed hemolysis in a concentration-dependent manner [260], and that 100µM 
SC-polyP inhibited the terminal pathway of complement with the same magnitude as LC-
polyP in serum. We found no such effect in whole blood when E.coli was used as a 
complement activator and blood was preincubated with 100 µM SC-polyP. These results 
seem conflicting, but it might be explained by the differences in study methods. 
Wijeyewickrema et al. used a buffer system with purified proteins, and Wat et al. used a 
system with 2% serum, which makes these systems suitable to study molecular mechanisms 
but they do not necessarily reflect what happens in vivo. Our whole blood system is more 
suitable for studying an in vivo situation as it represents an interface between an in vivo model 
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and an in vitro system. Our results indicate that the presence of blood cells and plasma in 
physiological concentrations interferes with the possible inhibitory function of SC-polyPs on 
complement activation and that SC-polyPs found in human platelets do not exert an inhibitory 
function on the complement system.  
 
The whole blood model used in this study gives us the opportunity to study the effects of 
polyPs in the presence of blood cells and plasma factors. Using lepirudin as an anticoagulant 
gives us a unique opportunity to analyze the initiation phase of thrombin generation. The fact 
that thrombin is inhibited in our model has to be kept in mind when interpreting the results, as 
it might influence the observations. On the other hand, inhibition of thrombin makes it 
possible to investigate the isolated effect of SC-polyPs on FXII activation without the 




6. Conclusions  
 
1. Low activity of the lectin pathway, reflected by MBL deficiency, and high activity of 
the classical pathway might be associated with risk of unprovoked VTE. Parameters of 
thrombin generation (lag-time and ETP) were associated with VTE risk, but displayed 
no associations with the activity of the lectin and classical complement pathways. These 
findings are hypothesis-generating and exploratory, and a larger prospective study is 
warranted to validate our findings.  
 
 
2. Complement activation in vivo, assessed by plasma levels of TCC, was associated 
with increased risk of VTE, and unprovoked events in particular. Genome-wide and 
complement-related gene variants were not associated with plasma levels of plasma 
TCC, suggesting that local or systemic environmental factors are the dominating 
determinants of plasma TCC. Functional studies are warranted to investigate the 
molecular mechanisms behind the association between plasma TCC and VTE risk.  
 
 
3. SC-polyphosphates activate the intrinsic pathway of coagulation through FXII in a 
human whole blood system where thrombin is blocked, but do not suppress E.coli-
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